- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 91,300 | 05.07.24 17:35:50 | -0,040 | -0,04% | 0,000 | 0,000 | 91,060 | 91,340 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 1.034,230 | 05.07.24 21:59:59 | +10,140 | +0,99% | 1.033,880 | 1.035,280 | 1.027,470 | 1.024,090 |
